SNORA33: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: SNORA33

NCBI ID: G594839

SNORA33

Other Name(s): ACA33 | Small nucleolar RNA, H/ACA box 33 | small nucleolar RNA, H/ACA box 33

SNORA33: A Potential Drug Target and Biomarker for Alzheimer's Disease

SNORA33 (ACA33) is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease. Its function and significance have led to its potential as a drug target or biomarker.

SNORA33 is a member of the resource-sharing receptor family, which is a large superfamily of transmembrane proteins that are involved in various cellular processes. It is composed of an N-terminal transmembrane domain, a coiled-coil region, and an C- terminal cytoplasmic domain. The N-terminal transmembrane domain contains a putative extracellular domain that is involved in the formation of the protein-protein interaction network and may be involved in the regulation of signaling pathways. The coiled-coil region is responsible for the protein's stability and functions as a conformational regulator. The C-terminal cytoplasmic domain is involved in the regulation of protein stability and may be involved in the degradation of SNORA33.

SNORA33 has been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease. Studies have shown that SNORA33 is overexpressed in the brains of individuals with Alzheimer's disease and that inhibition of its function has been shown to protect against the development of the disease. Additionally, SNORA33 has been shown to be involved in the regulation of neurotransmitter release and has been implicated in the development of neurodegenerative disorders.

SNORA33 has also been shown to be a potential drug target. Its function as a signaling protein and its involvement in the regulation of neurotransmitter release make it an attractive target for small molecule inhibitors. Several compounds have been shown to inhibit SNORA33's function, including inhibitors of its coiled-coil region and its N-terminal transmembrane domain. These compounds have been shown to protect against the development of neurodegenerative disorders and to improve cognitive function in animal models of the disease.

In addition to its potential as a drug target, SNORA33 has also been shown to be a potential biomarker. Its involvement in the regulation of neurotransmitter release and its expression in the nervous system make it an attractive candidate for use as a diagnostic or predictive marker for neurodegenerative disorders. Several studies have shown that SNORA33 is significantly reduced in the brains of individuals with Alzheimer's disease and that its levels are increased in the pre-clinical stages of the disease. These findings suggest that SNORA33 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

In conclusion, SNORA33 is a protein that has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease. Its function and significance have led to its potential as a drug target or biomarker. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Small Nucleolar RNA, H/ACA Box 33

The "SNORA33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets